These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 18834631)

  • 1. Allogeneic CD3/CD28 cross-linked Th1 memory cells provide potent adjuvant effects for active immunotherapy of leukemia/lymphoma.
    Har-Noy M; Zeira M; Weiss L; Fingerut E; Or R; Slavin S
    Leuk Res; 2009 Apr; 33(4):525-38. PubMed ID: 18834631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Completely mismatched allogeneic CD3/CD28 cross-linked Th1 memory cells elicit anti-leukemia effects in unconditioned hosts without GVHD toxicity.
    Har-Noy M; Zeira M; Weiss L; Slavin S
    Leuk Res; 2008 Dec; 32(12):1903-13. PubMed ID: 18565579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
    Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
    Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [New strategies in cancer immunotherapy].
    Ruan RS; Xu KC
    Zhonghua Zhong Liu Za Zhi; 2011 Dec; 33(12):943-6. PubMed ID: 22340107
    [No Abstract]   [Full Text] [Related]  

  • 5. CD137 enhances cytotoxicity of CD3(+)CD56(+) cells and their capacities to induce CD4(+) Th1 responses.
    Zhu BQ; Ju SW; Shu YQ
    Biomed Pharmacother; 2009 Aug; 63(7):509-16. PubMed ID: 19019623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dendritic cell vaccines for leukemia patients.
    Schmitt A; Hus I; Schmitt M
    Expert Rev Anticancer Ther; 2007 Mar; 7(3):275-83. PubMed ID: 17338648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Products of anti-CD3/anti-CD28 activated lymphocytes induce differentiation and maturation of dendritic cells and have adjuvant-like activity in vitro and in vivo.
    Harris KM; Lenz P; Hankey KG; MacVittie T; Farese A; Nakajima K; Hasumi K; Mann DL
    Clin Immunol; 2008 Oct; 129(1):58-68. PubMed ID: 18691939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of moderate exercise training on T-helper cell subpopulations in elderly people.
    Shimizu K; Kimura F; Akimoto T; Akama T; Tanabe K; Nishijima T; Kuno S; Kono I
    Exerc Immunol Rev; 2008; 14():24-37. PubMed ID: 19203082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-localized ligation of CD3 and CD28 with systemic regulatory T-cell depletion induces potent innate and adaptive antitumor responses.
    Lee CH; Chiang YH; Chang SE; Chong CL; Cheng BM; Roffler SR
    Clin Cancer Res; 2009 Apr; 15(8):2756-66. PubMed ID: 19318495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancement of Th1 immune response by CD8alpha(+) dendritic cells loaded with heat shock proteins enriched tumor extract in tumor-bearing mice.
    Azadmehr A; Pourfathollah AA; Amirghofran Z; Hassan ZM; Moazzeni SM
    Cell Immunol; 2009; 260(1):28-32. PubMed ID: 19712929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia.
    Horton HM; Bernett MJ; Pong E; Peipp M; Karki S; Chu SY; Richards JO; Vostiar I; Joyce PF; Repp R; Desjarlais JR; Zhukovsky EA
    Cancer Res; 2008 Oct; 68(19):8049-57. PubMed ID: 18829563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An effective tumor vaccine optimized for costimulation via bispecific and trispecific fusion proteins.
    Aigner M; Janke M; Lulei M; Beckhove P; Fournier P; Schirrmacher V
    Int J Oncol; 2008 Apr; 32(4):777-89. PubMed ID: 18360705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Do we have memory of danger as well as antigen?
    Noble A
    Trends Immunol; 2009 Apr; 30(4):150-6. PubMed ID: 19286426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune responses in patients with metastatic renal cell carcinoma treated with dendritic cells pulsed with tumor lysate.
    Soleimani A; Berntsen A; Svane IM; Pedersen AE
    Scand J Immunol; 2009 Nov; 70(5):481-9. PubMed ID: 19874553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer.
    Jasani B; Navabi H; Adams M
    Vaccine; 2009 May; 27(25-26):3401-4. PubMed ID: 19200817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccines in lymphoma.
    Levy R
    Clin Adv Hematol Oncol; 2004 Jul; 2(7):424, 427. PubMed ID: 16163215
    [No Abstract]   [Full Text] [Related]  

  • 17. Antitumor IgE adjuvanticity: key role of Fc epsilon RI.
    Nigro EA; Brini AT; Soprana E; Ambrosi A; Dombrowicz D; Siccardi AG; Vangelista L
    J Immunol; 2009 Oct; 183(7):4530-6. PubMed ID: 19748979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancement of anti-tumor immunity by high levels of Th1 and Th17 with a combination of dendritic cell fusion hybrids and regulatory T cell depletion in pancreatic cancer.
    Yamamoto M; Kamigaki T; Yamashita K; Hori Y; Hasegawa H; Kuroda D; Moriyama H; Nagata M; Ku Y; Kuroda Y
    Oncol Rep; 2009 Aug; 22(2):337-43. PubMed ID: 19578774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of optimized cryptic peptides for immunotherapy.
    Menez-Jamet J; Kosmatopoulos K
    IDrugs; 2009 Feb; 12(2):98-102. PubMed ID: 19204883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extracellular domain of 4-1BBL enhanced the antitumoral efficacy of peripheral blood lymphocytes mediated by anti-CD3 x anti-Pgp bispecific diabody against human multidrug-resistant leukemia.
    Guo H; Jiang W; Liu W; Gao Y; Yang M; Zhou Y; Wang J; Qi J; Cheng X; Zhu Z; Yang C; Xiong D
    Cell Immunol; 2008 Feb; 251(2):102-8. PubMed ID: 18482719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.